revenu guidanc forecast rel
forecast instrument revenu consum revenu
light instrument revenu shortfal seem time relat consum revenu
headwind may persist revenu guid street remain
market perform headwind subsid outlook improv
revenu y/i forecast
low end guidanc consensu instrument revenu
forecast manag note mass cytometri instrument
slip quarter due fund delay consum revenu
forecast manag note headwind includ inventori stock among
microfluid custom new mass cytometri custom take longer
expect ramp base guidanc appear complet transitori see
gross margin forecast consensu
decreas year year attribut product mix instrument price
sg expens forecast percentag sale
opex absolut basi line guidanc
revenu guid consensu previou
forecast midpoint manag indic mass cytometri pull-through
expect come guidanc rang return guid rang
opex guid total cash outflow guid
clearli disappoint quarter revenu guid flat q/q
compani could clear seemingli low hurdl addit manag note
headwind expect persist like challeng least near-
get midpoint guidanc assum mass cytometri placement
flat q/q microfluid instrument revenu y/i mass cytometri pull-
guid rang pull-through microfluid instrument
class low end guidanc rang consid setup quit achiev
also consid potenti upsid limit base call commentari
peer group current trade ev/sal arriv price target
use in-lin peer group multipl appli revis revenu
forecast
pleas see page report import disclosur
believ move stabil recoveri continu view
uniqu asset number potenti acquir like optim asset valu
provid downsid protect continu believ mass cytometri
franchis differenti ampl growth potenti view valuat full
level envis get construct imag cytof franchis
materi expand address opportun solid consist quarterli execut
continu stabl growth restor genom busi manag
outlin long-term strateg plan address competit structur dynam
contribut demand albeit
dv growth rate expect price
increment revenu contribut
much green space remain target
contribut stronger expect
issu ifc correct earli
strong ip product line make
increas competit attent
larger player begin neg impact
unabl manag oper
spend grow
dv growth rate slower expect
synergi abund
sluggish sale low consum
technolog enabl rapid effici highli parallel reproduc analysi
tens-to-hundr genet marker across hundreds-or-thousand dna sampl
hour instead day week technolog support genomics-bas applic
single-cel gene express high sampl throughput snp genotyp ground-
break capabl digit pcr autom target enrich next-
gener sequenc earli compani acquir dv expand singl cell
cowen compani
revenu guid annual consum util estim per activ instrument analyt cytometri pull-through note guid rang commentari providedaccessarray pull-through note guid rang count pull-through note guid rang revenu y/i forecast low end guidanc consensu instrument revenu forecast mass cytometri instrument slip quarter due fund consum revenu forecast manag note inventori stock microfluid custom new mass cytometri custom take longer expect margin forecast consensu decreas year year due product mix instrument price expens forecast percentag sale sg expens forecast percentag sale cowen vs consensu mm except ep incom statement mm except ep select revenu metric mm except servic revenu y/i consum revenu y/i forecast manag indic pull-through instrument segment came guid rang see part due inventori stock new custom take longer expect ramp among instrument revenu y/i forecast manag note mass cytometri weak quarter primarili due nih fund delay rel model mass cytometri placement like instrument light biomark placement like instrument juno placement like instrument placement like line cowen
compani report cowen compani
mm except cagrcommentstot revenu revenu revenu growth revenu growth growth salesproduct cowen
compani report thomson eikon cowen compani
mm except revenu sale product develop gener oper opex marginnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmgrowthnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmoth income/expens count gross op consensu estim cowen
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
risk medic life scienc tool sector may includ reduct delay research
develop budget govern fund reduc delay purchas
health care hospit custom increas extend regulatori hurdl process
regul product increas depend volatil emerg market revenu
profit gener macroeconom challeng
make invest recommend earli stage pre-commerci ls dt
compani base upon assess technolog probabl market success
competit regulatori reimburs etc potenti market opportun
event success howev compani lack tradit and/or matur
financi metric believ good methodolog assign specif
target price stock
risk downsid includ limit achiev product develop
timelin receiv regulatori approv need addit capit due cash burn
infring product liabil lawsuit competit manag execut
risk upsid includ lower expect competit pressur product upgrad
occur earlier forecast greater anticip purchas non-academ
custom new pipelin candid quicker expect adopt newli
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock thermo fisher scientif secur
cowen compani llc manag co-manag public offer past month
cowen compani llc receiv compens invest bank servic past month
past month client cowen compani llc cowen compani llc provid provid invest bank servic
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
inform herein base sourc believ reliabl guarante us purport complet statement summari avail data
opinion express herein statement judgment date subject chang without notic opinion recommend herein take
account individu client circumst object need intend recommend invest strategi recipi report must make
independ decis regard secur subject research report case secur financi instrument may difficult valu sell reliabl
inform valu risk relat secur financi instrument may difficult obtain extent report discuss legal proceed issu
prepar express intend express legal conclus opinion advic salespeopl trader profession may provid oral written
market commentari trade strategi client reflect opinion contrari opinion express research princip trade area invest
busi may make invest decis inconsist recommend view express research cowen compani llc maintain physic electron
procedur inform barrier address flow inform among depart within cowen compani llc order prevent avoid conflict
interest respect analyst recommend
import disclosur regard compani subject research report pleas contact complianc depart cowen compani llc lexington
avenu floor new york ny addit import disclosur except valuat method risk avail firm disclosur
websit http //cowen bluematrix com/sellside/disclosur action
equiti research price target cowen compani llc assign price target compani cover equiti research unless note otherwis equiti research price target
issuer stock repres valu analyst reason expect stock reach perform period twelv month price target equiti secur
report consid context prior publish cowen compani llc equiti research report includ disclosur equiti report
firm disclosur websit may may includ equiti research price target well develop relat issuer industri financi market
equiti research price target valuat methodolog risk associ achiev given equiti research price target pleas see analyst equiti research report
publish target
cowen cross-asset research due natur fix incom market issuer debt secur issuer discuss cowen cross-asset research report
assign rate price target may continu follow accordingli investor must regard brand report provid stand-alon analysi reflect
analyst opinion date report expect continu analysi addit report relat issuer debt secur issuer
time time cowen cross-asset research analyst provid invest recommend secur subject report recommend intend
time date public within paramet specifi individu report cowen cross-asset research invest recommend made
strictli case-by-cas basi recommend provid part overarch rate system set consist appli benchmark view express
cross-asset research report may differ view offer firm equiti research report prepar client
notic uk investor public produc cowen compani llc regul unit state finra commun person kind
describ articl servic market act promot order must transmit person without
notic european union investor individu produc recommend requir obtain certain licens financi regulatori author finra review
author current licens statu histori employ histori report regulatori custom disput crimin matter via brokercheck finra http //
brokercheck finra org/ individu licens statu finra constru endors finra gener biograph inform also avail
research analyst www cowen com
addit complet preced recommend histori relat recommend research report avail http //cowen bluematrix com/sellside/
recommend contain report produc august et dissemin august et
copyright user agreement gener inform relat report
cowen compani llc right reserv member nyse finra sipc research report prepar exclus use cowen client may
reproduc display modifi distribut transmit disclos whole part form manner other outsid organ without express prior
written consent cowen cowen research report distribut simultan client elig receiv research report unauthor use disclosur
